Literature DB >> 32206947

High-protein diet and omega-3 fatty acids improve redox status in olanzapine-treated rats.

Miroslav Mitrovic1, Tamara Nikolic Turnic2, Vladimir Zivkovic3, Zarko Pavic4, Aleksandra Vranic2, Ivan Srejovic3, Jasmina Sretenovic3, Sergey Bolevich5, Vladimir Lj Jakovljevic6,7.   

Abstract

The present study aimed to estimate the effects of high-protein diet (PD)-isolated whey protein and omega-3 fatty acids-docosahexaenoic and eicosapentaenoic acid on oxidative parameters of rats treated with Olanzapine (OLZ). Experiments were carried out on 8-week-old Wistar albino male rats (n = 64) weighing 200 ± 20 g. By dietary and pharmacological treatment, all animals were divided into 8 groups: 1. CTRL group; 2. CTRL + OLZ group; 3. CTRL + FA group; 4. CTRL + OLZ + FA group; 5. PD group; 6. PD + OLZ group; 7. PD + FA group; 8. PD + OLZ + FA group. After 6 weeks of pharmacological/diet treatment, all animals were sacrificed to collect blood samples and determine the biomarkers of oxidative stress. The following oxidative stress markers were measured spectrophotometrically: superoxide anion radical (O2-), hydrogen peroxide (H2O2), nitric oxide (NO-), index of lipid peroxidation measured as TBARS, reduced glutathione, catalase and superoxide dismutase. The study has shown that Olanzapine treatment was associated with increased release of pro-oxidants and diminished activity of anti-oxidant markers. Additional supplementation with PD and FA succeeded in abolishing the negative influence in most of the measured parameters. However, these beneficial impacts were stronger in the case of their separate application, which could be the practical and clinical importance of these results.

Entities:  

Keywords:  High-protein diet; Olanzapine; Omega-3 fatty acids; Oxidative stress; Rats

Mesh:

Substances:

Year:  2020        PMID: 32206947     DOI: 10.1007/s11010-020-03718-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  30 in total

1.  Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial.

Authors:  Feikang Xu; Weixing Fan; Weiping Wang; Wei Tang; Fuyin Yang; Yi Zhang; Jun Cai; Lisheng Song; Chen Zhang
Journal:  Psychopharmacology (Berl)       Date:  2018-12-05       Impact factor: 4.530

2.  Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients.

Authors:  J K Yao; S Leonard; R D Reddy
Journal:  Schizophr Res       Date:  2000-03-16       Impact factor: 4.939

3.  Olanzapine modulation of hepatic oxidative stress and inflammation in socially isolated rats.

Authors:  Nevena Todorović; Nada Tomanović; Peter Gass; Dragana Filipović
Journal:  Eur J Pharm Sci       Date:  2015-10-19       Impact factor: 4.384

4.  The genotoxic and oxidative damage potential of olanzapine in vitro.

Authors:  Hasan Türkez; Başak Toğar
Journal:  Toxicol Ind Health       Date:  2010-06-11       Impact factor: 2.273

5.  Catalase in vitro.

Authors:  H Aebi
Journal:  Methods Enzymol       Date:  1984       Impact factor: 1.600

Review 6.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Involvement of oxidative stress and mitochondrial/lysosomal cross-talk in olanzapine cytotoxicity in freshly isolated rat hepatocytes.

Authors:  Aziz Eftekhari; Yadollah Azarmi; Alireza Parvizpur; Mohammad Ali Eghbal
Journal:  Xenobiotica       Date:  2015-09-12       Impact factor: 1.908

Review 8.  Dopamine partial agonists: a new class of antipsychotic.

Authors:  Jeffrey A Lieberman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial.

Authors:  Toktam Faghihi; Adel Jahed; Javad Mahmoudi-Gharaei; Vandad Sharifi; Shahin Akhondzadeh; Padideh Ghaeli
Journal:  Daru       Date:  2012-10-04       Impact factor: 3.117

10.  Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia.

Authors:  Hideaki Katagiri; Masanori Taketsuna; Shinpei Kondo; Kenta Kajimoto; Etsuko Aoi; Yuka Tanji
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-23       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.